Online inquiry

IVTScrip™ mRNA-Anti-CD40, CHIR-12,12(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5866MR)

This product GTTS-WQ5866MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CD40 gene. The antibody can be applied in Chronic lymphocytic leukemia (CLL), Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001250.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 958
UniProt ID P25942
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD40, CHIR-12,12(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ5866MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15187MR IVTScrip™ mRNA-Anti-TNF, TA-650(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA TA-650
GTTS-WQ4967MR IVTScrip™ mRNA-Anti-GP, c2G4-N(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA c2G4-N
GTTS-WQ13065MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, PEG-IFN-SA(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA PEG-IFN-SA
GTTS-WQ1833MR IVTScrip™ mRNA-Anti-CFD, AFD Anti-fD(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AFD Anti-fD
GTTS-WQ6597MR IVTScrip™ mRNA-Anti-DPEP3, DC-1728001(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA DC-1728001
GTTS-WQ13187MR IVTScrip™ mRNA-Anti-PCSK9, PF-04950615(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA PF-04950615
GTTS-WQ9713MR IVTScrip™ mRNA-Anti-CD3E&GPRC5D, JNJ-64407564(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA JNJ-64407564
GTTS-WQ7906MR IVTScrip™ mRNA-Anti-MAG, GSK-249320(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA GSK-249320
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW